Does Enoxaparin treatment have any effects on the placenta in women with unexplained histories of habitual abortion? A case control study
Keywords:
Abortion, induced, Chorionic villi, Enoxaparin, Heparin, low-molecular-weight, Apoptosis, PlacentaAbstract
BACKGROUND: It is very common to offer low molecular weight heparin (LMWH) medications to women with unexplained habitual abortion, to increase the livebirth rate. Although no benefit from LMWH has been clearly demonstrated, examination of the effects of enoxaparin on placental structure is lacking. OBJECTIVE: To assess placental structural changes in pregnancies treated with enoxaparin, compared with controls. DESIGN AND SETTING: Case-control study in an obstetrics and gynecology unit of a tertiary-level university hospital in Turkey. METHODS: Forty patients who had had term pregnancies and live births but also histories of habitual abortion were recruited for this study. Placentas were sampled using a systematic random sampling method. Tissue samples were obtained, embedded and sectioned for routine histological analyses. Hematoxylin and eosin staining was used. Surface area and length estimates from placental components were evaluated by using Image J. Cell proliferation and apoptosis were also assessed via immunohistochemistry. RESULTS: There were no significant differences between the groups regarding maternal age, abortion rate, birth weight or gestational age. Comparison of the enoxaparin and control groups showed that there were no significant differences in terms of surface area and ratios of placental components. We found that Bcl-2 was generally expressed at high levels in the enoxaparin group, while there was no difference in terms of Ki-67 between the groups. CONCLUSIONS: This study demonstrates that enoxaparin did not show any significant effect on the placental structure of cases that had histories of habitual abortion.
Downloads
References
Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod. 2006;21(9):2216-22. PMID: 16707507; doi: 10.1093/humrep/del150.
Jeve YB, Davies W. Evidence-based management of recurrent miscarriages. J Hum Reprod Sci. 2014;7(3):159-69. PMID: 25395740; doi: 10.4103/0974-1208.142475.
Ford HB, Schust DJ. Recurrent pregnancy loss: etiology, diagnosis, and therapy. Rev Obstet Gynecol. 2009;2(2):76-83. PMID: 19609401.
Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2008;2:CD003511. PMID: 18425891; doi: 10.1002/14651858.CD003511.pub2.
Rai R, Backos M, Baxter N, Chilcott I, Regan L. Recurrent miscarriage--an aspirin a day? Hum Reprod. 2000;15:2220-3.
Tulppala M, Marttunen M, Söderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod. 1997;12(7):1567-72. PMID: 9262298; doi: https://doi.org/10.1093/humrep/12.7.1567.
de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev. 2014;(7):CD004734. PMID: 24995856; doi: 10.1002/14651858.CD004734.pub4.
Dolitzky M, Inbal A, Segal Y, et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006;86(2):362-6. PMID: 16769056; doi: 10.1016/j.fertnstert.2005.12.068.
Maged AM, Abdelhafiz A, Al Mostafa WA, et al. The role of prophylactic use of low dose aspirin and calheparin in patients with unexplained recurrent abortion. Gynecol Endocrinol. 2016;32(12):970-2. PMID: 27426855; doi: 10.1080/09513590.2016.1203408.
Lu X, Liu Z, Zhang X, et al. Prothrombotic state of patients with unexplained recurrent spontaneous abortion. Int J Gynaecol Obstet. 2015;131(2):161-5. PMID: 26296564; doi: 10.1016/j.ijgo.2015.04.049.
Fox H, Herd ME, Harilal KR. Morphological changes in the placenta and decidua after induction of abortion by extra-amniotic prostaglandin. Histopathology. 1978;2(2):145-51. PMID: 669592; doi: 10.1111/j.1365-2559.1978.tb01702.x.
Atia TA. Placental apoptosis in recurrent miscarriage. Kaohsiung J Med Sci. 2017;33(9):449-52. PMID: 28865602; doi: 10.1016/j.kjms.2017.06.012.
Boyd TK, Redline RW. Chronic histiocytic intervillositis: a placental lesion associated with recurrent reproductive loss. Hum Pathol. 2000;31(11):1389-96. PMID: 11112214.
Redline RW, Zaragoza M, Hassold T. Prevalence of developmental and inflammatory lesions in nonmolar first-trimester spontaneous abortions. Hum Pathol. 1999;30(1):93-100. PMID: 9923934; doi: 10.1016/s0046-8177(99)90307-6.
Sebire NJ, Backos M, Goldin RD, Regan L. Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome. BJOG. 2002;109(5):570-3. PMID: 12066949; doi: 10.1111/j.1471-0528.2002.00077.x.
Sebire NJ, Backos M, El Gaddal S, Goldin RD, Regan L. Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients. Obstet Gynecol. 2003;101(2):258-63. PMID: 12576248; doi: 10.1016/s0029-7844(02)02385-2.
Sebire NJ, Fox H, Backos M, et al. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod. 2002;17(4):1067-71. PMID: 11925407; doi: 10.1093/humrep/17.4.1067.
Roberts VH, Gaffney JE, Lewandowski KS, et al. A standardized method for collection of human placenta samples in the age of functional magnetic resonance imaging. Biotechniques. 2019;67 (2):45-9. PMID: 31184493; doi: 10.2144/btn-2019-0029.
Mayhew TM. Stereology and the placenta: where’s the point? -- a review. Placenta. 2006;27 Suppl A:S17-25. PMID: 16406003; doi: 10.1016/j.placenta.2005.11.006.
Sengupta J, Dhawan L, Lalitkumar PG, Ghosh D. A multiparametric study of the action of mifepristone used in emergency contraception using the Rhesus monkey as a primate model. Contraception. 2003;68(6):453-69. PMID: 14698076; doi: 10.1016/s0010-7824(03)00108-2.
Sgarbosa F, Barbisan LF, Brasil MA, et al. Changes in apoptosis and Bcl-2 expression in human hyperglycemic, term placental trophoblast. Diabetes Res Clin Pract. 2006;73(2):143-9. PMID: 16563550; doi: 10.1016/j.diabres.2005.12.014.
Ishibashi H, Suzuki T, Suzuki S, et al. Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab. 2003;88(5):2309-17. PMID: 12727990; doi: 10.1210/jc.2002-021353.
Teasdale F. Idiopathic intrauterine growth retardation: histomorphometry of the human placenta. Placenta. 1984;5(1):83-92. PMID: 6728834; doi: 10.1016/s0143-4004(84)80051-x.
Mayhew TM, Bowles C, Orme G. A stereological method for testing whether or not there is random deposition of perivillous fibrin-type fibrinoid at the villous surface: description and pilot applications to term placentae. Placenta. 2000;21(7):684-92. PMID: 10985972; doi: 10.1053/plac.2000.0551.
Geenes VL, Lim YH, Bowman N, et al. A placental phenotype for intrahepatic cholestasis of pregnancy. Placenta. 2011;32(12):1026-32. PMID: 22015023; doi: 10.1016/j.placenta.2011.09.006.
Vora S, Shetty S, Khare M, Ghosh K. Placental histomorphology in unexplained foetal loss with thrombophilia. Indian J Med Res. 2009;129(2):144-9. PMID: 19293440.
Van Horn JT, Craven C, Ward K, Branch DW, Silver RM. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta. 2004;25(7):642-8. PMID: 15193871; doi: 10.1016/j.placenta.2003.12.006.
Mills CD. M1 and M2 Macrophages: Oracles of Health and Disease. Crit Rev Immunol. 2012;32(6):463-88. PMID: 23428224; doi: 10.1615/critrevimmunol.v32.i6.10.
Rull K, Tomberg K, Köks S, et al. Increased placental expression and maternal serum levels of apoptosis-inducing TRAIL in recurrent miscarriage. Placenta. 2013;34 (2):141-8. PMID: 23290504; doi: 10.1016/j.placenta.2012.11.032.
Kim KR, Jun SY, Kim HJ, Rio JY. Implantation site intermediate trophoblasts in placenta cretas. Mod Pathol. 2004;17(12):1483-90. PMID: 15205687; doi: 10.1038/modpathol.3800210.
Ishihara N, Matsuo H, Murakoshi H, et al. Changes in proliferative potential, apoptosis and Bcl-2 protein expression in cytotrophoblasts and syncytiotrophoblast in human placenta over the course of pregnancy. Endocr J. 2000;47(3):317-27. PMID: 11036876; doi: 10.1507/endocrj.47.317.
Danihel L, Gomolcák P, Korbel M, et al. Expression of proliferation and apoptotic markers in human placenta during pregnancy. Acta Histochem. 2002;104(4):335-8. PMID: 12553697; doi: 10.1078/0065-1281-00683.
Kelten C, Zekioglu O, Terek C, Ozdemir N, Düzcan E. Expression of ki-67, bcl-2 and bax in the first trimester abortion materials. Turk J Pathol. 2010;26(1):31-7. Available from: Available from: http://www.turkjpath.org/pdf/pdf_TPD_1407.pdf Accessed in 2019 (Dec 13).
